Atlas Trials

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

Clinical trial NCT03818685 · UNKNOWN

Trial details

NCT number
NCT03818685
Sponsor
Centre Leon Berard
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerTriple Negative Breast Neoplasms
Start date
2019-07-02
Primary completion
2024-03-15
Enrollment
95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.